ATE516796T1 - Granulat mit einem pharmazeutischen wirkstoff und einem emulgator und herstellungsverfahren dafür - Google Patents

Granulat mit einem pharmazeutischen wirkstoff und einem emulgator und herstellungsverfahren dafür

Info

Publication number
ATE516796T1
ATE516796T1 AT07808579T AT07808579T ATE516796T1 AT E516796 T1 ATE516796 T1 AT E516796T1 AT 07808579 T AT07808579 T AT 07808579T AT 07808579 T AT07808579 T AT 07808579T AT E516796 T1 ATE516796 T1 AT E516796T1
Authority
AT
Austria
Prior art keywords
emulsifier
granulate
active substance
pharmaceutically active
granules
Prior art date
Application number
AT07808579T
Other languages
English (en)
Inventor
Hubert Clemens Pellikaan
Pieter Sebastiaan Vermeulen
Johannes Caspar Mathias Elizabeth Bender
Cid Maria Vanesa Fernandez
Original Assignee
Echo Pharmaceuticals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37809291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE516796(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Echo Pharmaceuticals Bv filed Critical Echo Pharmaceuticals Bv
Application granted granted Critical
Publication of ATE516796T1 publication Critical patent/ATE516796T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT07808579T 2006-09-15 2007-09-14 Granulat mit einem pharmazeutischen wirkstoff und einem emulgator und herstellungsverfahren dafür ATE516796T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06120741 2006-09-15
PCT/NL2007/050448 WO2008033023A2 (en) 2006-09-15 2007-09-14 Granulate containing a pharmaceutically active substance and anemulsifier and method for its manufacture

Publications (1)

Publication Number Publication Date
ATE516796T1 true ATE516796T1 (de) 2011-08-15

Family

ID=37809291

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07808579T ATE516796T1 (de) 2006-09-15 2007-09-14 Granulat mit einem pharmazeutischen wirkstoff und einem emulgator und herstellungsverfahren dafür

Country Status (10)

Country Link
US (1) US20100034888A1 (de)
EP (1) EP2061427B1 (de)
JP (2) JP2010503663A (de)
CN (1) CN101594848B (de)
AT (1) ATE516796T1 (de)
AU (1) AU2007295178B2 (de)
CA (1) CA2664311C (de)
ES (1) ES2370062T3 (de)
PL (1) PL2061427T3 (de)
WO (1) WO2008033023A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE516796T1 (de) * 2006-09-15 2011-08-15 Echo Pharmaceuticals Bv Granulat mit einem pharmazeutischen wirkstoff und einem emulgator und herstellungsverfahren dafür
US9308175B2 (en) * 2006-09-15 2016-04-12 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
EP2298286B8 (de) * 2009-09-18 2017-08-09 SiTec PharmaBio SL Verfahren zur Entwässerung von Produktpulvern
US8383851B2 (en) 2010-09-15 2013-02-26 Caravan Ingredients Inc. Lactylate synthesis methods using dilactides
CN104363890B (zh) * 2012-05-07 2018-01-26 回音制药公司 含有大麻素的颗粒物及其制备方法和含有该颗粒物的口服给药单元
CN105848646B (zh) 2013-10-29 2019-10-22 艾克制药有限公司 包含大麻二酚的压制片剂、其制造方法以及此类片剂在口服治疗精神病症或焦虑症中的用途
CN105873566B (zh) * 2013-10-29 2019-06-07 艾克制药有限公司 含有δ9-四氢大麻酚的压制片剂、其制造方法及此类片剂在口服治疗中的用途
CN104688734B (zh) * 2013-12-04 2017-08-15 长春海悦药业股份有限公司 一种含有苯磺酸左旋氨氯地平的药物组合物
CA3176674A1 (en) 2015-05-18 2016-11-24 5071, Inc. Homogenous cannabis compositions and methods of making the same
CA3031533A1 (en) * 2016-07-25 2018-02-01 Ebbu Inc. New cannabis tablet formulations and compositions and methods of making the same
CA3069694A1 (en) * 2017-07-14 2019-01-17 5071, Inc. Cannabinoid compositions and methods of preparation thereof
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
US11633351B2 (en) 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
CA3040547C (en) 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
JP7736671B2 (ja) * 2019-08-30 2025-09-09 イーヴィー エスエー 充填顆粒、これらの製造方法及びこれらの使用
JP2023526098A (ja) 2020-05-18 2023-06-20 オレクソ・アクチエボラゲット 薬物送達のための新しい医薬組成物
CA3238850A1 (en) 2021-11-25 2023-06-01 Jonas Savmarker Pharmaceutical composition comprising adrenaline
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3406497A1 (de) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
IL78930A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
GB8730011D0 (en) * 1987-12-23 1988-02-03 Smithkline Dauelsberg Pharmaceutical compositions
DE3744329A1 (de) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
ATE142484T1 (de) * 1992-01-17 1996-09-15 Alfatec Pharma Gmbh Wirkstoff-enthaltende festkörper mit einem gerüst aus hydrophilen makromolekülen und verfahren zu ihrer herstellung
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
AU676315B2 (en) * 1993-06-30 1997-03-06 Takeda Chemical Industries Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
EP1066761B1 (de) * 1999-07-06 2004-09-29 DSM IP Assets B.V. Zusammensetzung, die fettlösliche Substanzen in einer Kohlenhydratmatrix enthält
FR2797398B1 (fr) * 1999-08-11 2002-10-18 Mainelab Microparticules pour administration pulmonaire
JP4467883B2 (ja) * 2001-02-14 2010-05-26 ジーダブリュー・ファーマ・リミテッド 医薬製剤
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
WO2002070013A1 (en) * 2001-03-06 2002-09-12 Kyowa Hakko Kogyo Co., Ltd. Utilization of spray-dried powder containing sugar alcohol
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
UA79281C2 (en) * 2002-04-03 2007-06-11 Solvay Pharm Bv Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof
US20060257463A1 (en) * 2002-05-31 2006-11-16 University Of Mississippi Transmucosal delivery of cannabinoids
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
DE10248619A1 (de) * 2002-10-18 2004-04-29 Bayer Ag Verfahren zur Herstellung pulverförmiger Wirkstoff-Formulierungen mit kompressiblen Fluiden
GB0300339D0 (en) * 2003-01-08 2003-02-05 Bradford Particle Design Ltd Particle formation
US7423004B2 (en) * 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
WO2004071645A2 (en) * 2003-02-07 2004-08-26 Ferro Corporation Method and apparatus for supercritical fluid assisted particle production
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
EP1641437A4 (de) * 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp Feste dispersion von tacrolimus
US20050163843A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Alprazolam formulations
BRPI0513395A (pt) * 2004-07-16 2008-05-06 Novartis Ag uso de um esteróide para aumentar a permeabilidade cutánea
EP1757361A1 (de) * 2005-08-23 2007-02-28 Feyecon Development & Implementation B.V. Verfahren zur Herstellung von Kapseln durch Ausfällung
DE602005023670D1 (de) * 2005-12-22 2010-10-28 Inst Nat Sante Rech Med Verfahren zur herstellung von teilchen aus einer emulsion in überkritischem oder flüssigem co2
ATE516796T1 (de) * 2006-09-15 2011-08-15 Echo Pharmaceuticals Bv Granulat mit einem pharmazeutischen wirkstoff und einem emulgator und herstellungsverfahren dafür

Also Published As

Publication number Publication date
EP2061427A2 (de) 2009-05-27
CA2664311A1 (en) 2008-03-20
EP2061427B1 (de) 2011-07-20
JP2014114302A (ja) 2014-06-26
AU2007295178A1 (en) 2008-03-20
CN101594848A (zh) 2009-12-02
WO2008033023A2 (en) 2008-03-20
US20100034888A1 (en) 2010-02-11
CA2664311C (en) 2015-08-18
WO2008033023A3 (en) 2008-09-12
CN101594848B (zh) 2014-10-29
ES2370062T3 (es) 2011-12-12
JP2010503663A (ja) 2010-02-04
PL2061427T3 (pl) 2011-12-30
AU2007295178B2 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
ATE516796T1 (de) Granulat mit einem pharmazeutischen wirkstoff und einem emulgator und herstellungsverfahren dafür
WO2008137787A3 (en) Combination therapy with a compound acting as a platelet adp receptor inhibitor
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
AU2002326072A1 (en) Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
WO2006125620A3 (en) Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
WO2005082089A3 (en) Immunosuppressant compounds and compositions
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
HRP20120264T1 (hr) Farmaceutski sastavi neuroaktivnog steroida i njihove uporabe
TW200635618A (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
MA33058B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan avec stabilite amelioree
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
WO2008048469A3 (en) Controlled-release coated dosage forms containing galantamine
IL158082A0 (en) Amlodipine camsylate and methods for the preparation thereof
CY1110913T1 (el) Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα
AU2002368152A1 (en) 3,6-disubstituted azabicyclo (3.1.0)hexane derivatives useful as muscarinic receptor antagonists
WO2007148341A3 (en) Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
WO2007054257A3 (en) Indene derivatives, their preparation and use as medicaments
HRP20110023T1 (hr) Smanjenje prekomjerne težine ili pretilosti
AU2003214535A8 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004067510A8 (en) 3,6-disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
WO2006035282A3 (en) Muscarinic receptor antagonists

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties